프루퀸티닙|HMPL-013
|
|
프루퀸티닙|HMPL-013 속성
- 끓는 점
- 600.5±55.0 °C(Predicted)
- 밀도
- 1.302±0.06 g/cm3(Predicted)
- 저장 조건
- Sealed in dry,Store in freezer, under -20°C
- 용해도
- DMSO에 용해됩니다(최대 5mg/ml).
- 산도 계수 (pKa)
- 14.35±0.46(Predicted)
- 물리적 상태
- 고체
- 물리적 상태
- 단단한 모양
- 색상
- 하얀색
- 안정성
- 제공된 대로 구매일로부터 1년 동안 안정적입니다. DMSO의 솔루션은 최대 1개월 동안 -20°에서 보관할 수 있습니다.
- InChI
- InChI=1S/C21H19N3O5/c1-11-19(20(25)22-2)13-6-5-12(7-16(13)28-11)29-21-14-8-17(26-3)18(27-4)9-15(14)23-10-24-21/h5-10H,1-4H3,(H,22,25)
- InChIKey
- BALLNEJQLSTPIO-UHFFFAOYSA-N
- SMILES
- O1C2=CC(OC3=C4C(=NC=N3)C=C(OC)C(OC)=C4)=CC=C2C(C(NC)=O)=C1C
안전
- 위험 및 안전 성명
- 위험 및 사전주의 사항 (GHS)
그림문자(GHS): | ||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
신호 어: | Warning | |||||||||||||||||||||||||||||||||||
유해·위험 문구: |
|
|||||||||||||||||||||||||||||||||||
예방조치문구: |
|
프루퀸티닙|HMPL-013 C화학적 특성, 용도, 생산
개요
Fruquintinib is a VEGFR inhibitor (IC50s = 33, 35, and 0.5 nM for VEGFR1, -2, and -3, respectively). It also inhibits RET, FGFR1, and c-Kit (IC50s = 128, 181, and 458 nM, respectively) in a panel of 253 kinases. Fruquintinib inhibits VEGF-A-induced proliferation of human umbilical vein endothelial cells (HUVECs) and VEGF-C-induced proliferation of human lymphatic endothelial cells (HLECs; IC50s = 1.7 and 4.2 nM, respectively). It decreases tube formation by HUVECs by 74 and 94% when used at concentrations of 30 and 300 nM, respectively. Fruquintinib (0.5-20 mg/kg per day for 21 days) reduces tumor growth in BGC-823, HT-29, Caki-1, and NCI H460 mouse xenograft models.용도
Fruquintinib (HMPL-013) is a highly selective VEGFR-1/2/3 tyrosine kinase inhibitor. It was approved by the FDA on 8 November 2023 for the treatment of adult patients with metastatic colorectal cancer. and these patients had previously received fluoropyrimidine, oxaliplatin and irinotecan chemotherapy, anti-vascular endothelial growth factor therapy, and anti-epidermal growth factor receptor (EGFR) therapy. Fruquintinib has also been shown to improve cognitive deficits and pathological changes in a mouse model of cerebral amyloid angiopathy (CAA).용도
Fruquintinib is a multi-targeted tyrosine kinase inhibitor, a third-line regimen involved in the treatment of advanced non-small cell lung cancer in humans. Fruquintinib is a potent, highly selective and orally active inhibitor of VEGFR1, 2, 3 tyrosine kinases.프루퀸티닙|HMPL-013 준비 용품 및 원자재
원자재
준비 용품
프루퀸티닙|HMPL-013 공급 업체
글로벌( 162)공급 업체
공급자 | 전화 | 이메일 | 국가 | 제품 수 | 이점 |
---|---|---|---|---|---|
Wuhan Jingkang en Biomedical Technology Co., Ltd | +8613720134139 |
orders@jknbiochem.com | China | 4692 | 58 |
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD. | +86-18600796368 +86-18600796368 |
sales@sjar-tech.com | China | 74 | 58 |
Zhengzhou Anbu Chem Co.,Ltd | +86-0371-88006763; +8615988602810 |
sales@anbuchem.com | China | 3000 | 58 |
Apeloa production Co.,Limited | +8619933239880 |
admin@apcl.com.cn | China | 853 | 58 |
ATK CHEMICAL COMPANY LIMITED | +undefined-21-51877795 |
ivan@atkchemical.com | China | 32760 | 60 |
Hubei xin bonus chemical co. LTD | 86-13657291602 |
linda@hubeijusheng.com | CHINA | 22968 | 58 |
BOC Sciences | +1-631-485-4226 |
inquiry@bocsci.com | United States | 19553 | 58 |
Zhengzhou Alfa Chemical Co.,Ltd | +8618530059196 |
sale04@alfachem.cn | China | 13056 | 58 |
TargetMol Chemicals Inc. | +1-781-999-5354 +1-00000000000 |
marketing@targetmol.com | United States | 19892 | 58 |
HANGZHOU CLAP TECHNOLOGY CO.,LTD | 86-571-88216897,88216896 13588875226 |
sales@hzclap.com | CHINA | 6313 | 58 |
프루퀸티닙|HMPL-013 관련 검색:
Everolimus
Imatinib
HACHIMYCIN
CINITAPRIDE HYDROGEN TARTRATE
Panitumumab
Capecitabine
Sorafenib
1-[[4-[(4-Fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-2-propanol
Afatinib (BIBW 2992)
Gefitinib
Lapatinib
17-AAG
Erlotinib hydrochloride
Dasatinib
Imatinib mesylate
Bevacizumab
Icotinib (Hydrochloride)
Icotinib